Advances in Mass Spectrometry Enabled Drug Discovery

October 29, 2024
Tuesday
8:20 AM to 5:35 PM

475 Via Ortega
Stanford, CA
Mackenzie Room, Jen-Hsun Huang Engineering Center

About Event

The inaugural Stanford Cancer Institute Advances in Mass Spectrometry Enabled Drug Discovery symposium on October 29, 2024 will bring together leading experts in academia and industry to explore current challenges and opportunities and recent achievements across diverse applications in drug development.

This field has revolutionized ligand and target discovery by enabling the detection of interactions proteome-wide. Chemoproteomic techniques targeting reactive residues have grown and expanded the scope of covalent ligand discovery. Mass spectrometry instrumentation continues to improve, deepening proteomic coverage, accuracy, and sensitivity while becoming more accessible.

The symposium is open to Stanford faculty, students, and postgraduates, as well as those outside of Stanford who are interested in diving into the cutting-edge world of proteomics. Join us for this all-day dynamic learning experience to discuss the exciting progress in mass spectrometry-based proteomics.

Agenda & Speakers

Agenda
Speakers

7:30 - 8:20 am
Registration Open & Continental Breakfast

8:20 - 8:30 am
Welcome
Nathanael Gray, PhD
Stanford University

8:30 - 10:10 am
Session I: Using mass spectrometry platforms for ligand discovery

Matt Patricelli, PhD
Vividion Therapeutics

Sherry Niessen, PhD
Belharra Therapeutics

Katelyn Cassidy, PhD
C4 Therapeutics

Paola Castaldi, PhD
Matchpoint Therapeutics

10:10- 10:35 am
Session 1 Panel Discussion

10:35 -10:45 am
Break

10:45 - 11:35 am
Session 2: Expanding covalency in drug design

Kevan Shokat, PhD
UCSF

Jack Taunton, PhD
UCSF

11:35 - 11:55 am
Session 2 Panel Discussion

12:00 - 1:00 pm
Lunch

1:00 - 1:50 pm
Session 3: MS Technology & Discovery Proteomics

Brian Searle, PhD
Ohio State University

Peter Jackson, PhD
Stanford University

1:50 - 2:10 pm
Session 3 Panel Discussion

2:10 - 2:50 pm

Trainee Lightning Talks

Brendan Dwyer, PhD
Stanford University

Shizhong Dai, PhD
Stanford University

Steven Shuken, PhD
Harvard University

2:00 - 2:10 pm
Break

2:10 - 3:25 pm

Session 4: Advancing activity-based protein profiling

Ben Cravatt, PhD
Scripps Research Institute

Keriann Backus, PhD
UCLA

Ekaterina Vinogradova, PhD
Rockefeller University

3:25 - 3:45 pm
Session 4 Panel Discussion

3:45 - 3:55 pm
Break

3:55 - 5:10 pm
Session 5: Developing proximity-based therapeutics

Katherine Donovan, PhD
Dana Farber Cancer Institute

Pete Wildes, PhD
Revolution Medicines

5:10 - 5:30 pm
Session 5 Panel Discussion

5:30 - 5:35 PM
Ending remarks

Matt Patricelli, PhD
Vividion Therapeutics

Nathanael Gray, PhD
Stanford University

5:35 - 6:15 pm
Reception

Keriann Backus, PhD

Assistant Professor, Biological Chemistry, Chemistry and Biochemistry
PI, The Backus Lab
UCLA

Katelyn Cassidy, PhD

Senior Proteomics Scientist
Team Leader
C4 Therapeutics

Paola Castaldi, PhD

Senior Vice President, Head of Platform and Chemical Biology
Matchpoint Therapeutics

Ben Cravatt, PhD

Professor and Gilula Chair, Chemical Biology
PI, The Cravatt Lab
Scripps Research Institute

Katherine Donovan, PhD

Lead Scientist/Managing Director
Fischer Labs
Dana Farber Cancer Institute

Peter Jackson, PhD

Professor of Microbiology and Immunology, Baxter Labs, and of Pathology
Faculty Director, Stanford Cancer Center Proteomics
Faculty Director, Stanford University Mass Spectrometry
PI, The Jackson Lab
Stanford University

Sherry Niessen, PhD

Vice President, Head of Platform & Proteomics
Belharra Therapeutics

Matt Patricelli, PhD

Chief Scientific Officer
Vividion Therapeutics

Brian Searle, PhD

Assistant Professor, Department of Biomedical Informatics
Ohio State University Medical Center.
Courtesy Assistant Professor, Department of Chemistry and Biochemistry, Ohio State University

Kevan Shokat, PhD

Professor, Department of Cellular and Molelcular Pharmacology
PI, The Shokat Lab
UCSF

Jack Taunton, PhD

Professor, Cellular Molecular Pharmacology
PI, The Taunton Lab
UCSF

Ekaterina Vinogradova, PhD

Assistant Professor
Head of Laboratory of Chemical Immunology and Proteomics
PI, The Vinogradova Lab
Rockefeller University

Pete Wildes, PhD

Vice President, Cancer Biology
Revolution Medicine

Registration

Seating is limited. Please register if you are planning to attend.

Early bird registration is available until September 13, 2024.
Regular pricing will start September 14, 2024.
Registration will close on October 22, 2024.

Early Bird Price
May 13 - Sept 13

$25 - Students/Grad Students/Postdocs
$50 - Academic (Faculty/Staff)
$100 - Industry Professionals

Regular Price
Sept 14 - Oct 22

$50 - Students/Grad Students/Postdocs
$75 - Academic (Faculty/Staff)
$200 - Industry Professionals

Location and Parking

Jen-Hsun Huang Engineering Center building

Mackenzie Room, 3rd Floor
Jen-Hsun Huang Engineering Center
475 Via Ortega, Stanford CA 94305
Google Maps

Parking

There are two parking garages near the Huang Engineering Center. If you are a visitor to campus, you can use ParkMobile in visitor parking areas. The hourly rate is $4.46 and the daily rate is $35.68. Click here for more information on visitor parking.

Parking Structure 2
285 Panama St, Stanford CA 94305
Visitor parking is available on the ground floor

Roble Field Garage
369 Santa Teresa St, Stanford CA 94305
Underground garage located between Santa Teresa and Panama St

Organizers

Nathanael Gray, PhD

Krishnan-Shah Family Professor, Chemical and Systems Biology
Co-director, Cancer Drug Discovery
Co-leader, Cancer Therapeutics Research Program
Program Leader, Small Molecule Drug Discovery for the Innovative Medicines Accelerator
PI, The Gray Lab
Stanford University

Brendan Dwyer, PhD

Postdoctoral Scholar
Stanford Cancer Center
Stanford University

Stanford Cancer Institute

Search Stanford Cancer Institute

Stanford Cancer Institute